<script type="text/javascript">
<!--
document.write('<div id="oa_widget"></div>');
document.write('<script type="text/javascript" src="https://www.openaire.eu/index.php?option=com_openaire&view=widget&format=raw&projectId=undefined&type=result"></script>');
-->
</script>

COPY SCRIPT

For further information contact us at helpdesk@openaire.eu

Clinical Outcome Assessments Toolbox for Radiopharmaceuticals

descriptionPublicationkeyboard_double_arrow_right Article , Other literature type 10 Oct 2019 United States Publisher:Frontiers Media SAJournal:Frontiers in Oncology, volume 9 (eissn: 2234-943X,

Authors: Kunos, Charles A; Capala, Jacek; Dicker, Adam P; Movsas, Benjamin; Ivy, Susan Percy; Minasian, Lori M;

doi: 10.3389/fonc.2019.01028

pmid: 31649885

pmc: PMC6795707

Clinical Outcome Assessments Toolbox for Radiopharmaceuticals

- Summary
- Subjects
- Metrics

Abstract

For nearly 40 years, the U.S. National Cancer Institute (NCI) has funded health-related quality-of-life (HRQOL) and symptom management in oncology clinical trials as a method for including a cancer patient's experience during and after treatment. The NCI's planned scope for HRQOL, symptom and patient-reported outcomes management research is explained as it pertains to radiopharmaceutical clinical development. An effort already underway to support protocol authoring via an NCI Cancer Therapy Evaluation Program (CTEP) Centralized Protocol Writing Service (CPWS) is described as this service aids incorporation of HRQOL, symptom and patient-reported outcomes management research into sponsored protocols.

Country

United States

Related Organizations

Henry Ford Hospital
United States
National Institutes of Health
United States
Henry Ford Health System
United States
National Heart Lung and Blood Institute
United States
National Cancer Institute
United States

View all View all

Keywords

patient reported outcome (PRO), 610, Neoplasms. Tumors. Oncology. Including cancer and carcinogens, radiotherapy adverse effects, radiopharmaceutical, clinical outcome assessment, Oncology, 616, cancer, radiotherapy, RC254-282, digital device usage

Impact byBIP!

	citations This is an alternative to the "Influence" indicator, which also reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically).	3
	popularity This indicator reflects the "current" impact/attention (the "hype") of an article in the research community at large, based on the underlying citation network.	Average
	influence This indicator reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically).	Average
	impulse This indicator reflects the initial momentum of an article directly after its publication, based on the underlying citation network.	Average